Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The £13m drug discovery partnership between Oxford University, Oxford Sciences Innovation and Evotec supported 12 new projects in first year of operation.

Thomas Hanke © John Cairns
Thomas Hanke, Expert-in-Residence at Evotec

LAB282, the £13m drug discovery partnership between Oxford University, Oxford Sciences Innovation and Evotec, is celebrating its first year of operation after successfully accelerating 12 drug discovery and development projects at the University.

In total, the partnership has provided 14 awards, both small and large scale.

In its fourth and latest round of awards, LAB282 backed the following Oxford projects:

  • Validation of novel targets for myelofibrosis, a severe bone marrow disorder.
  • Development of glucosidase II interface inhibitors; towards a novel class of broad-spectrum antivirals.
  • Discovery of potent inhibitors to DarG antitoxins as a first-in-class anti-microbial concept.
  • Advancing the development of evasins, a novel class of chemokine-trap to treat inflammatory disorders.

Find out more (Oxford University Innovation website)

Similar stories

University spinout PepGen awarded major financing to target Duchenne muscular dystrophy

Awards and Appointments General Innovation

PepGen, a therapeutics company targeting severe neuromuscular diseases, including Duchenne muscular dystrophy (DMD), has closed a $45 million Series A funding round led by RA Capital Management with participation from Oxford Sciences Innovation (OSI), the company’s original seed investor.

Evox Therapeutics announces launch of strategic collaboration with the University of Oxford

General Innovation

Collaboration with world-renowned research centre to accelerate development of exosome therapies for rare diseases

BioEscalator’s resident biotech Base Genomics acquired by Exact Sciences

General Innovation

Oxford Sciences Innovation (OSI) recently announced the acquisition of its portfolio company, Base Genomics, by US-based early cancer diagnostic leaders, Exact Sciences, for $410m. The partnership will enable Base Genomics to significantly accelerate its clinical and commercial development here in Oxford, potentially unlocking a new era of preventative medicine and improved patient outcomes.

Comparison of five tests used to detect COVID-19 antibodies shows Siemens and Oxford assays met regulatory targets

Coronavirus COVID-19 Innovation Research

New research shows that, in a head-to-head comparison of five tests used to detect COVID-19 antibodies (known as ‘immunoassays’), an assay manufactured by Siemens and one developed by an academic partnership led by the University of Oxford had the most accurate results. The study is published in The Lancet Infectious Diseases.

QUOD enters partnership with Evotec

General Innovation Research

Evotec SE, a drug discovery and development solutions company, today announced a partnership agreement with the University of Oxford regarding access to biospecimens from the biobank Quality in Organ Donation (QUOD), an initiative of the Nuffield Department of Surgical Sciences (NDS) at the University of Oxford in close collaboration with the National Health Service Blood and Transplant (NHSBT) organisation in the UK.